Deerfield Management Company, L.P. (Series C) Edgewise Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,067,320 shares of EWTX stock, worth $27.7 Million. This represents 0.62% of its overall portfolio holdings.
Number of Shares
2,067,320
Previous 2,078,509
0.54%
Holding current value
$27.7 Million
Previous $45.7 Million
40.73%
% of portfolio
0.62%
Previous 1.16%
Shares
5 transactions
Others Institutions Holding EWTX
# of Institutions
191Shares Held
118MCall Options Held
54.3KPut Options Held
70.1K-
Orbimed Advisors LLC San Diego, CA15.5MShares$208 Million7.26% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.9MShares$133 Million2.84% of portfolio
-
Baker Bros. Advisors LP New York, NY7.31MShares$97.8 Million0.97% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.14MShares$82.2 Million3.76% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$80.6 Million0.0% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $846M
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...